Literature DB >> 8899054

Botulinum toxin A injection in the treatment of hemifacial spasm.

R S Chen1, C S Lu, C H Tsai.   

Abstract

UNLABELLED: There are conflicting reports concerning the variation in duration of symptoms relief for patients with hemifacial spasm who have undergone several injections of botulinum A toxin (BOTX-A). We present our experience of BOTX-A injections in Taiwanese patients to analyze this issues, and to inspect whether the efficacy of treatment depends on the pre-injection severity. MATERIAL AND
METHOD: From July 1992 to December 1994, 137 patients received injections of BOTX-A. We used objective and subjective score system to evaluate the efficacy and side effects of BOTX-A injection.
RESULTS: The overall successful rate of substantial relief of spasm was 88%. The mean duration of response was 20 weeks. Patents with more severe spasm tended to have shorter duration of improvement. The effects of consecutive injections remained fairly constant over the first 4 injections.
CONCLUSION: The BOTX-A injection is an effective and safe treatment for patients with hemifacial spasm and the effect could be sustained over the consecutive injections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899054     DOI: 10.1111/j.1600-0404.1996.tb07053.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  [Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].

Authors:  J Winterhoff; R Laskawi
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

2.  Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm.

Authors:  Nicola Tambasco; Simone Simoni; Elisa Sacchini; Paolo Eusebi; Erica Marsili; Pasquale Nigro; Elona Brahimi; Federico Paolini Paoletti; Michele Romoli; Paolo Calabresi
Journal:  Neurol Sci       Date:  2019-05-10       Impact factor: 3.307

Review 3.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

4.  Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters.

Authors:  Bettina Wabbels; Ali Yaqubi
Journal:  J Neural Transm (Vienna)       Date:  2021-05-08       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.